Literature DB >> 19756663

[Inflammatory myopathies].

B Schoser1.   

Abstract

Inflammatory myopathies cover infectious, focal and immunogenic myopathies. This review focuses on the clinical features, diagnostic techniques, pathogenesis and therapy of immunogenic myopathies. Besides myositis associated with other autoimmune disorders, dermatomyositis is the most common immunogenic myopathy. The independent diagnosis of polymyositis has come under debate, since within this group of patients some are now diagnosed as having either hereditary muscular dystrophy with inflammatory signs or inclusion body myositis (IBM). Even more strikingly, patients diagnosed with sporadic IBM may now be diagnosed with either a form of hereditary IBM or with a form belonging to the group of protein aggregate myopathies or myofibrillar myopathies. This re-classification reflects the well-known and clinically evident therapeutic dilemma in many of these patients. Thus the indication for muscle biopsy or rebiopsy requires new consideration and attention.

Entities:  

Mesh:

Year:  2009        PMID: 19756663     DOI: 10.1007/s00393-009-0511-x

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  16 in total

1.  Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis.

Authors:  Elisabeth Dion; Patrick Cherin; Christine Payan; Jean-Charles Fournet; Thomas Papo; Thierry Maisonobe; Eric Auberton; Olivier Chosidow; Pierre Godeau; Jean-Charles Piette; Serge Herson; Philippe Grenier
Journal:  J Rheumatol       Date:  2002-09       Impact factor: 4.666

Review 2.  Defining cancer risk in dermatomyositis. Part I.

Authors:  V Madan; H Chinoy; C E M Griffiths; R G Cooper
Journal:  Clin Exp Dermatol       Date:  2009-04-14       Impact factor: 3.470

Review 3.  Myofibrillar myopathies: a clinical and myopathological guide.

Authors:  Rolf Schröder; Benedikt Schoser
Journal:  Brain Pathol       Date:  2009-07       Impact factor: 6.508

4.  GNE mutations in an American family with quadriceps-sparing IBM and lack of mutations in s-IBM.

Authors:  Olavo M Vasconcelos; Raghavan Raju; Marinos C Dalakas
Journal:  Neurology       Date:  2002-12-10       Impact factor: 9.910

Review 5.  Muscle imaging in inflammatory myopathies.

Authors:  C D Reimers; M Finkenstaedt
Journal:  Curr Opin Rheumatol       Date:  1997-11       Impact factor: 5.006

6.  Pathological consequences of VCP mutations on human striated muscle.

Authors:  Christian U Hübbers; Christoph S Clemen; Kristina Kesper; Annett Böddrich; Andreas Hofmann; Outi Kämäräinen; Karen Tolksdorf; Maria Stumpf; Julia Reichelt; Udo Roth; Sabine Krause; Giles Watts; Virginia Kimonis; Mike P Wattjes; Jens Reimann; Dietmar R Thal; Katharina Biermann; Bernd O Evert; Hanns Lochmüller; Erich E Wanker; Benedikt G H Schoser; Angelika A Noegel; Rolf Schröder
Journal:  Brain       Date:  2006-09-19       Impact factor: 13.501

Review 7.  Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.

Authors:  E H S Choy; J E Hoogendijk; B Lecky; J B Winer
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

Review 8.  Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia.

Authors:  Conrad C Weihl; Alan Pestronk; Virginia E Kimonis
Journal:  Neuromuscul Disord       Date:  2009-04-19       Impact factor: 4.296

9.  SLCO1B1 variants and statin-induced myopathy--a genomewide study.

Authors:  E Link; S Parish; J Armitage; L Bowman; S Heath; F Matsuda; I Gut; M Lathrop; R Collins
Journal:  N Engl J Med       Date:  2008-07-23       Impact factor: 91.245

Review 10.  Exercise effects in patients with adult idiopathic inflammatory myopathies.

Authors:  Helene Alexanderson
Journal:  Curr Opin Rheumatol       Date:  2009-03       Impact factor: 5.006

View more
  2 in total

Review 1.  [Myositides: What is the current situation?].

Authors:  K M Rösler; O Scheidegger
Journal:  Z Rheumatol       Date:  2015-08       Impact factor: 1.372

2.  [Severe dysphagia and erythrodermia in a 59-year-old man].

Authors:  M A Zuber; M Kouba; S E Rudolph; M Weller; P Hrdlicka
Journal:  Internist (Berl)       Date:  2013-03       Impact factor: 0.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.